【摘要】 目的观察艾迪注射液联合CHOP方案化疗治疗弥漫大B细胞淋巴瘤的疗效、免疫功能及感染率的不同。方法选取我院2016年9月-2017年6月经病理证实的弥漫大B细胞淋巴瘤80例且无条件使用利妥昔单抗患者,随机分为两组。对照组40例,给予标准CHOP方案化疗,试验组40例,给予标准CHOP方案联合艾迪注射液治疗。治疗结束后对比两组疗效、免疫指标及化疗期间感染率发生情况。结果实验组免疫指标、感染率与对照组相比,差异有统计学意义,但在近期有效率无明显差别。结论艾迪注射液有提高弥漫大B细胞淋巴瘤患者免疫功能和减少感染风险的作用,值得临床推广应用。更多还原

【Abstract】 Objective To observe the difference in efficacy,immune function and infection rate of Aidi injection combined with CHOP regimen in the treatment of diffuse large B-cell lymphoma. Methods There are 80 cases of diffuse large B-cell lymphoma had been selected from September 2016 to June 2017,they were randomly divided into two groups. 40 patients in the control group were treated with standard CHOP regimen,and 40 patients in the experimental group were treated with standard CHOP regimen combined with Aidi injection. After treatment,the efficacy,immune index and infection rate of the two groups were compared. Results There were statistically significant differences in immune index and infection rate between the experimental group and the control group. Conclusion Aidi injection can improve the immune function and reduce the risk of infection in patients with diffuse large b-cell lymphoma.更多还原